Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635

Biomea Fusion, Inc. (Nasdaq: BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases, today announced that on June 1, 2024, the compensation committee of Biomea's board of directors granted one new employee non-qualified stock options to purchase an aggregate of 25,000 shares of the Company's common stock. The shares underlying the employee's stock options will vest 116 on a quarterly basis over four years, subject to the employee's continued employment with the Company on such vesting dates.

The above-described award was made pursuant to the terms of Biomea's 2023 Inducement Equity Plan (the "Plan") and was granted as an inducement material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The Plan was adopted by Biomea's board of directors on November 17, 2023.

About Biomea Fusion

Biomea Fusion is a clinical stage biopharmaceutical company focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response.

We are utilizing our proprietary FUSION™ System to discover, design and develop a pipeline of next-generation covalent-binding small molecule medicines designed to maximize clinical benefit for patients with various cancers and metabolic diseases, including diabetes. We aim to have an outsized impact on the treatment of disease for the patients we serve. We aim to cure.

Visit us at biomeafusion.com and follow us on LinkedIn , Twitter and Facebook .


Contact: Investor Relations Chunyi Zhao, PhD Associate Director of Investor Relations & Corporate Development czhao@biomeafusion.com

Primary Logo

News Provided by GlobeNewswire via QuoteMedia

BMEA:US
The Conversation (0)
Biomea Fusion Inc.

Biomea Fusion Inc.

Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.

Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold

Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold

Biomea Fusion, Inc. ("Biomea" or the "Company") (Nasdaq: BMEA), announced that the Company has received notice from the U.S. Food and Drug Administration (FDA) that a full clinical hold has been placed on Biomea's ongoing Phase III clinical trials of the Company's investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 and COVALENT-112), respectively. The Company will continue ongoing safety and efficacy data collection during the hold.

"We respect the FDA's decision and agree that patient safety is paramount and our top priority. We are fully collaborating and working diligently with the FDA to put a plan in place as quickly as possible to ensure patient safety and look forward to resuming the studies once we have authorization from the FDA. The results to date have supported that BMF-219 is generally well-tolerated and can restore glucose-controlled insulin production and improve glycemic control. Based on the totality of the safety and efficacy data for BMF-219 in diabetes to date, we remain committed to advancing BMF-219 with its potentially transformative profile," stated Thomas Butler, Biomea Fusion's Chief Executive Officer and Chairman of the Board.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes

Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes

Biomea Fusion, Inc. ("Biomea") (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers, today announced the completion of enrollment of the first three dose expansion arms of COVALENT-111, with a total of over 260 type 2 diabetes patients enrolled.

The COVALENT-111 study is a multi-site, randomized, double-blind, placebo-controlled Phase I/II study. Phase II consists of multiple dose escalation and dose expansion cohorts including adult patients with type 2 diabetes uncontrolled by standard of care medicines. The dose escalation phase is evaluating BMF-219 dosed over 4 weeks with 22 weeks follow-up off treatment. The first three arms (A, B, C) of the expansion phase are evaluating BMF-219 dosed over 8 and 12 weeks at 100 mg and 200 mg with up to 40 weeks of follow-up off treatment.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights

Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights

  • Reported positive data from the escalation portion of Phase 1/2 study (COVALENT-111) in type 2 diabetes patients, displaying durable improved glycemic control while off therapy for 22 weeks, supporting the disease-modifying potential of BMF-219 to address a root cause of diabetes: a loss of healthy, insulin-producing beta cells
  • Announced initial clinical data from our Phase 2 study (COVALENT-112) in type 1 diabetes from the first two type 1 diabetes patients dosed with BMF-219 and demonstrated early signs of clinical activity with improved measures of beta-cell function after initial treatment with BMF-219
  • We expect a reduction in operating expenses in the second half of the year due to the near completion of enrollment of the first three arms of our type 2 diabetes study and near completion of enrollment of the open label portion of our type 1 diabetes study. Cash position of $145.3 million at the end of the first quarter of 2024

Biomea Fusion, Inc. ("Biomea" or "the Company") (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers, reported first quarter 2024 financial results and corporate highlights.

"Over the last two months we have seen a significant increase in the rate of enrollment for the expansion phase cohorts of our Phase 1/2 study, COVALENT-111, investigating BMF-219 in patients with type 2 diabetes. There is currently a waitlist for the fourth cohort which we expect will open for enrollment in the second half of this year.  We have also seen a significant increase in the rate of enrollment of our Phase 2 study, COVALENT-112, in patients with type 1 diabetes following the press release which provided an early look at the first two patients dosed with BMF-219. Here we highlighted the first two patients dosed with BMF-219 demonstrated an increase in C-peptide Index (Amount of C-peptide secreted per unit of glucose) during the early stages of treatment. This is truly an exciting and validating update on our progress in type 1 diabetes. Patients with type 2 diabetes have lost about 50% of their pool of beta cells while patients with type 1 diabetes have lost at least 90% of their beta-cell pool at diagnosis and are therefore not able to produce sufficient insulin to address the glucose levels in their blood. Currently approved treatments for diabetes are mostly chronic treatments helping patients to reduce the blood glucose while the mass and function of the beta cells continues to decline. We have now demonstrated in multiple preclinical experiments that BMF-219 has the potential to address diabetes at the root cause level by improving the function and mass of beta cells. The data we reported from the escalation portion of our clinical study COVALENT-111 in the first quarter of 2024 demonstrated for the first time how an agent can achieve durable glycemic control while patients are off therapy, supporting the disease-modifying potential of BMF-219 to address a root cause of diabetes," stated Thomas Butler, Biomea Fusion's Chief Executive Officer and Chairman of the Board. "In 2024, we expect to continue to advance our clinical programs with BMF-219 in diabetes and plan to report multiple data readouts throughout the remainder of the year, including topline Week 26 data of over 200 patients from our Phase 1/2 study, COVALENT-111, in type 2 diabetes, and topline Week 26 data from approximately 40 patients enrolled in the open label portion of our Phase 2 study, COVALENT-112, in type 1 diabetes patients. Our goal is to deliver a short-term, non-chronic treatment that will reconstitute insulin-producing beta cells, allowing the patients' own bodies to normalize blood sugar levels."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635

Biomea Fusion, Inc. (Nasdaq: BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases, today announced that on May 1, 2024, the compensation committee of Biomea's board of directors granted 8 new employees non-qualified stock options to purchase an aggregate of 80,250 shares of the Company's common stock. The shares underlying each employee's stock options will vest 116 on a quarterly basis over four years, in each case subject to each such employee's continued employment with the Company on such vesting dates. All of the above-described awards were made under Biomea's 2023 Inducement Equity Plan (the "Plan").

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Silver47 Exploration - OTC Markets Request

Silver47 Exploration - OTC Markets Request

Silver47 Exploration Corp. (TSXV: AGA,OTC:AAGAF) (OTCQB: AAGAF) ("Silver47" or the "Company") confirms that, as previously announced on September 4, 2025, it has engaged Sideways Frequency LLC ("SFLLC") as an arms-length, third party firm contractually retained by the Company in accordance with routine industry practices to provide investor relations services for a 12 month term.

As part of the Company's efforts towards investor awareness, SFLLC organizes and facilitates the creation and distribution of promotional material concerning the Company and its common shares traded on the OTCQB marketplace (the "Promotional Material") on behalf of the Company. On September 10, 2025, the Company became aware that SFLLC had commenced distribution of Promotional Material which discussed the Company, its business and a general assessment of, and commentary on, the broader market for silver and silver exploration globally. The Promotional Material was available via email and online via click-through of digital media ads.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Vertex Minerals Limited  Corporate Presentation Mining Forum Americas

Vertex Minerals Limited Corporate Presentation Mining Forum Americas

Perth, Australia (ABN Newswire) - Flagship Project for Vertex Minerals Limited (ASX:VTX,OTC:VTXXF) (OTCMKTS:VTXXF) - Reward Gold Mine, Hill End Corporate Presentation to Mining Forum Americas.

- Commenced Gold processing with new Gekko Gravity Gold Plant

- 100% owned

- No hedge - No Secured debt - fully funded

- Low operating Cost

- High Grade Gold Resource and Reserve 225 ozs at 16.7g/t + more

- Inherited >AUD $50m of underground development

- 1.8M Au oz historically mined

- Reward sits below the Hawkins Hill Mine 435kozs at 309 g/t

- Up to 95% recovery by gravity processes only

- Big Gold System, ~21Miles (34km) with >3,000 old workings

*To view the presentation, please visit:
https://abnnewswire.net/lnk/484ZF4X8



About Vertex Minerals Limited:

Vertex Minerals Limited (ASX:VTX,OTC:VTXXF) is an Australian based gold exploration company developing its advanced Hargraves and Hill End gold projects located in the highly prospective Eastern Lachlan Fold Belt of Central West NSW. Other Company assets include the Pride of Elvire gold project and Taylors Rock gold/nickel/lithium project both located in the Eastern Goldfields of WA. The focus of Vertex Minerals is to advance the commercial production of gold from its NSW projects embracing an ethical and environmentally sustainable approach.



Source:
Vertex Minerals Limited

News Provided by ABN Newswire via QuoteMedia

Keep reading...Show less
Canada One Commences 2025 Field Work Program at Flagship, Copper Dome Project

Canada One Commences 2025 Field Work Program at Flagship, Copper Dome Project

Canada One Mining Corp. (TSXV: CONE) (OTC Pink: COMCF) (FSE: AU31) ("Canada One" or the "Company") is pleased to announce the launch of its 2025 field exploration program at its flagship Copper Dome Project ("Copper Dome", "Property" or "Project"), located 18 km south of Princeton, British Columbia.

2025 FIELD WORK PROGRAM HIGHLIGHTS

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Cygnus reports a 78% increase in M&I resource at its Chibougamau Copper-Gold Project

Cygnus reports a 78% increase in M&I resource at its Chibougamau Copper-Gold Project

HIGHLIGHTS:

  • Global Measured & Indicated Mineral Resource ("M&I") estimate of 6.4 Mt at 3.0% CuEq for 193kt CuEq and Inferred Mineral Resource of 8.5 Mt at 3.5% CuEq for 295 kt CuEq in accordance with JORC 2012 and CIM Definition Standards (CIM, 2014)
  • Total contained metal is exclusively Copper, Gold and Silver:
    • M&I: 149kt Cu, 167 koz Au & 1.6 Moz Ag (for 193 kt CuEq or 884 koz AuEq)
    • Inferred: 182 kt Cu, 454 koz Au & 2.2 Moz Ag (for 295 kt CuEq or 1.3 Moz AuEq)
  • This update includes an initial Mineral Resource Estimate ("MRE") for the new Golden Eye deposit and the other existing hub-and-spoke deposits of Corner Bay, Cedar Bay, Devlin, and Joe Mann
  • The initial high-grade Golden Eye resource contains:
    • Indicated: 91 koz @ 5.6 g/t AuEq
    • Inferred: 182 koz @ 4.6 g/t AuEq
  • The 78% tonnage increase in M&I Resources will underpin an updated Scoping Study / Preliminary Economic Assessment ("PEA"), which will also reflect the significant increase in commodity prices on the economics of the Project since the 2022 PEA completed by Doré Copper 1
  • Today's announcement demonstrates proven upside at the Chibougamau Project with two diamond drill rigs still turning and additional potential to add to the resource base
  • Chibougamau Project is a premier near-term development copper-gold opportunity with established infrastructure including a 900 ktpa processing facility, sealed highway, airport, regional rail infrastructure, and 25 kV hydro power to the processing site
  • The Project has excellent metallurgy with test work recoveries of up to 98.2% producing a high-quality clean copper concentrate of up to 29.6% 2
  • Cygnus is continuing to generate an exciting pipeline of exploration targets using its in-house AI-driven solution for the compilation of historic drill logs and maps; This work has proven highly successful and has helped deliver the initial Golden Eye MRE
  • The Company remains fully funded to drive further growth and the ongoing study work with A$23M cash at 30 June 2025
  • A new fly through video and resource presentation will be available in the coming week, given the finalisation of the MRE as announced today

Cygnus Executive Chairman David Southam said: "Within just nine months of acquiring the Chibougamau Project, we have been able to deliver a significant resource upgrade with substantial scope for further growth.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Redstone Drilling at Tollu Intersects 10m at 1.37% Cu

Redstone Drilling at Tollu Intersects 10m at 1.37% Cu

Redstone Resources (RDS:AU) has announced Redstone Drilling at Tollu Intersects 10m at 1.37% Cu

Download the PDF here.

Latest Press Releases

Related News